微创与开放扩大胰体尾切除联合多器官切除的术后与肿瘤学结局比较
本研究回顾性分析2009至2020年798例左侧胰腺导管腺癌行胰体尾切除患者,其中388例符合Miami指南定义的扩大胰体尾切除,217例接受微创手术、171例开放手术。微创组与开放组在严重并发症、90天死亡率和五年生存率上无显著差异,微创组辅助化疗启动时间有缩短趋势;联合血管切除是严重并发症的显著危险因素,预后更多由病理侵犯而非手术方式决定。
要点
- 微创扩大胰体尾切除在筛选的左侧胰腺癌中可行且安全,肿瘤学结局与开放手术相当。
- 联合血管切除与严重并发症显著相关(OR 3.642,95%CI 2.025-6.549,P<0.001)。
- 病理侵犯邻近器官与更差生存相关(HR 1.479,95%CI 1.133-1.930,P=0.004)。
核心结论
- 微创扩大胰体尾切除在怀疑多器官侵犯的左侧胰腺导管腺癌中可行且安全,肿瘤学结局与开放手术相当,并显示出更快恢复的信号。
- 预后似乎更多由病理侵犯驱动,而非手术方式或联合切除范围。
研究设计与样本
- 回顾性数据审查,纳入2009至2020年间798例左侧胰腺导管腺癌行胰体尾切除患者。
- 其中388例符合Miami国际循证指南定义的扩大胰体尾切除并纳入分析,217例接受微创扩大胰体尾切除,171例接受开放扩大胰体尾切除。
主要发现
- 两组临床病理特征和90天死亡率无显著差异。
- 严重并发症(CDC III级或以上)两组相似:微创组11.1%,开放组17.6%,P=0.052。
- 微创组辅助化疗启动时间相对开放组有缩短趋势:5.9 vs. 6.6周,P=0.061。
- 多变量分析显示联合血管切除是严重并发症的显著因素(OR 3.642,95%CI 2.025-6.549,P<0.001)。
- 五年生存率两组相当:微创组25.5%,开放组18.1%,P=0.132;更差生存与病理侵犯邻近器官(HR 1.479,95%CI 1.133-1.930,P=0.004)、术后并发症、R0切除、低分化、淋巴血管侵犯、神经周围侵犯及未完成辅助化疗相关。
临床怎么用
- 在筛选的左侧胰腺导管腺癌怀疑多器官侵犯患者中,微创扩大胰体尾切除可作为开放手术的可行替代。
- 联合血管切除患者需警惕严重并发症风险增高,应加强围术期管理。
- 病理侵犯邻近器官提示预后较差,术后应重视辅助化疗的完成。
局限性
- 回顾性研究设计。
- 单中心或有限中心数据,可能存在选择偏倚。
- 微创组与开放组的部分比较未达到统计学显著性,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimally invasive extended distal pancreatectomy (MIEDP) is often challenging for pancreatic ductal adenocarcinoma (PDAC) due to its aggressive invasion into adjacent organs or major blood vessels. This study aimed to compare the surgical and oncological outcomes of MIEDP and open-extended distal pancreatectomy (OEDP) for left-sided PDAC. METHODS: A retrospective data review was conducted for 798 patients with left-sided PDAC who underwent distal pancreatectomy between 2009 and 2020. Among these, 388 patients were included in the analysis who underwent extended distal pancreatectomy, as defined in the Miami International evidence-based guidelines. RESULTS: Of those 388 included patients, 217 underwent MIEDP and 171 OEDP. No significant differences were observed in the clinicopathological characteristics or 90-day mortality rates between the groups. Moreover, severe complications (CDC III or higher) were similar between groups (MIEDP: 11.1%; OEDP: 17.6%; P = 0.052). MIEDP was associated with a shorter time to adjuvant chemotherapy initiation relative to OEDP (5.9 vs. 6.6 weeks; P = 0.061). Multivariable analysis revealed that combined vessel resection was a significant factor for severe complications (OR: 3.642, 95% CI: 2.025-6.549; P < 0.001). The five-year survival rates were comparable (MIEDP: 25.5%; OEDP: 18.1%; P = 0.132). However, poorer survival was associated with pathological invasion of adjacent organs (HR: 1.479, 95% CI: 1.133-1.930; P = 0.004), postoperative complications, R0 resection, poor differentiation, lymphovascular invasion, perineural invasion, and failure to complete adjuvant chemotherapy. CONCLUSIONS: MIEDP is feasible and safe in selected left-sided PDAC with suspected multiorgan invasion and shows oncologic outcomes comparable to OEDP, with faster recovery signals. Prognosis appears driven more by pathological invasion than by surgical approach or extent of concomitant resection.
引用
- Park Y, Hwang DW, Lee JH, et al. Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal adenocarcinoma. Surg Endosc. 2025. PMID: 41345530. doi:10.1007/s00464-025-12452-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。